MX2019006863A - Inhibidores de heparanasa y uso de los mismos. - Google Patents

Inhibidores de heparanasa y uso de los mismos.

Info

Publication number
MX2019006863A
MX2019006863A MX2019006863A MX2019006863A MX2019006863A MX 2019006863 A MX2019006863 A MX 2019006863A MX 2019006863 A MX2019006863 A MX 2019006863A MX 2019006863 A MX2019006863 A MX 2019006863A MX 2019006863 A MX2019006863 A MX 2019006863A
Authority
MX
Mexico
Prior art keywords
heparanase inhibitors
compounds
heparanase
inhibitors
heparanse
Prior art date
Application number
MX2019006863A
Other languages
English (en)
Inventor
Nelms Keats
SCHWARTZ Brett
Jackson Colin
Banwell Martin
Hammond Edward
Original Assignee
Beta Therapeutics Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2017902346A external-priority patent/AU2017902346A0/en
Application filed by Beta Therapeutics Pty Ltd filed Critical Beta Therapeutics Pty Ltd
Publication of MX2019006863A publication Critical patent/MX2019006863A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Abstract

La invención se relaciona con compuestos de quinazolina funcionalizados, composiciones farmacéuticas que comprenden dichos compuestos, y el uso de dichos compuestos como inhibidores de heparanasa para el tratamiento de enfermedades o condiciones relacionadas con la actividad de la heparanasa.
MX2019006863A 2016-12-13 2017-12-13 Inhibidores de heparanasa y uso de los mismos. MX2019006863A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662433652P 2016-12-13 2016-12-13
AU2017902346A AU2017902346A0 (en) 2017-06-20 Methods of treating ocular disorders
PCT/AU2017/000270 WO2018107200A1 (en) 2016-12-13 2017-12-13 Heparanase inhibitors and use thereof

Publications (1)

Publication Number Publication Date
MX2019006863A true MX2019006863A (es) 2019-09-13

Family

ID=67057483

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019006863A MX2019006863A (es) 2016-12-13 2017-12-13 Inhibidores de heparanasa y uso de los mismos.

Country Status (12)

Country Link
US (1) US11718609B2 (es)
EP (1) EP3555051A4 (es)
JP (1) JP2020503377A (es)
KR (1) KR20190093214A (es)
CN (1) CN110291073A (es)
AU (1) AU2017376817B2 (es)
BR (1) BR112019012045A2 (es)
CA (1) CA3046997A1 (es)
IL (1) IL267238A (es)
MX (1) MX2019006863A (es)
RU (1) RU2019121873A (es)
WO (1) WO2018107200A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200360386A1 (en) * 2017-12-30 2020-11-19 Unity Biotechnology, Inc. Inhibitors of HSP90, PI3-Kinase, Proteasome, HDAC, and P97 Pathways for Selective Removal of Senescent Cells in the Treatment of Age Related Conditions
WO2020078455A1 (zh) * 2018-10-19 2020-04-23 南京明德新药研发有限公司 Tlr8激动剂
US20220202964A1 (en) * 2019-04-24 2022-06-30 University Of Florida Research Foundation, Incorporated Heparanase compounds and methods of use
CN111253326B (zh) * 2020-03-17 2020-12-08 河北美信医药科技有限公司 一种2-取代-4-位官能团化的n(o,s)-喹(唑)啉类衍生物及其应用
CN112375027B (zh) * 2020-12-07 2023-03-31 中国药科大学 吲哚磺酰胺类衍生物及其医药用途

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK140695C (da) 1976-05-07 1980-05-12 Synthelabo Analogifremgangsmaade til fremstilling af 2,4-diamino-6,7-dimethoxyquinazolinderivater eller syreadditionssalte heraf
FR2350101A1 (fr) * 1976-05-07 1977-12-02 Synthelabo Nouvelles guanidines cyclisees
US4668787A (en) 1985-12-20 1987-05-26 Ortho Pharmaceutical Corporation 5,6-dialkoxy-4-imino-2(1H)quinazolinone derivatives
US4717373A (en) 1986-09-08 1988-01-05 Mobil Oil Corporation Apparatus for sealing a hem in a moving web of film using angularly oriented hot wheels
PT93847A (pt) 1989-04-24 1990-11-20 Harvard College Processo para a preparacao de oligossacaridos de baixo peso molecular derivados de heparina ou de sulfato de heparano despolimerizados e de composicoes farmaceuticas que os contem
US5514667A (en) 1990-11-05 1996-05-07 Arthropharm Pty. Limited Method for topical treatment of herpes infections
AU1052492A (en) 1991-01-31 1992-08-06 Farmitalia Carlo Erba S.R.L. Synergistic composition comprising a fibroblast growth factor and a sulfated polylsaccharide, for use as antiviral agent
JP2657760B2 (ja) * 1992-07-15 1997-09-24 小野薬品工業株式会社 ４−アミノキナゾリン誘導体およびそれを含有する医薬品
EP0594877A1 (en) 1992-10-26 1994-05-04 National Science Council Imidazo(1,2-c)quinazoline derivates as antihyper tensives and anti dysurics
AU7520394A (en) 1993-08-13 1995-03-14 Glycomed Incorporated Bridged oligosaccharides and sulfated derivatives thereof
US5739115A (en) 1993-10-07 1998-04-14 Glycomed Incorporated Sulfated maltooligosaccharides with heparin-like properties
EP0722326A4 (en) 1993-10-07 1999-10-06 Glycomed Inc HIGHLY SULFATED MALTOOLIGOSSACCHARIDES WITH HEPARIN-LIKE PROPERTIES
AUPN261895A0 (en) 1995-04-28 1995-05-18 Australian National University, The Preparation and use of sulfated oligosaccharides
US5849709A (en) 1995-05-10 1998-12-15 Glycomed Incorporated Saccharopeptides and derivatives thereof
US5980865A (en) 1995-08-18 1999-11-09 Baker Norton Pharmaceuticals, Inc. Method for treating late phase allergic reactions and inflammatory diseases
US6562950B2 (en) 1997-09-02 2003-05-13 Insight Strategy & Marketing Ltd. Heparanase activity neutralizing anti-heparanase monoclonal antibody
GT199900185A (es) 1998-11-06 2001-04-18 Novedosa pirimidin-4-enamina como fungicida.
JP3032980B1 (ja) * 1999-06-14 2000-04-17 三協化学株式会社 ２―ピリジルピリジン誘導体の製造方法
IT1316986B1 (it) 2000-01-25 2003-05-26 Sigma Tau Ind Farmaceuti Derivati glicosamminoglicani parzialmente desolfatati nonanticoagulanti ad attivita' antiangiogenica.
AU2001293817A1 (en) * 2000-09-20 2002-04-02 Merck Patent Gmbh 4-amino-quinazolines
AU2002228317A1 (en) 2001-01-29 2002-08-12 Insight Strategy And Marketing Ltd Benz-1,3-azole derivatives and their uses as heparanase inhibitors
WO2002060375A2 (en) 2001-01-29 2002-08-08 Insight Strategy And Marketing Ltd Diphenyl ether derivatives and their uses as heparanase inhibitors
WO2002060867A2 (en) * 2001-01-29 2002-08-08 Insight Strategy And Marketing Ltd Carbazole derivatives and their uses as heparanase inhibitors
WO2002060373A2 (en) 2001-01-29 2002-08-08 Insight Strategy And Marketing Ltd Indole derivatives and their uses as heparanase inhibitors
AR035791A1 (es) 2001-03-23 2004-07-14 Bayer Corp Compuesto n,n-diheterociclico de amina, inhibidor de la rho-quinasa, su uso para la fabricacion de un medicamento y proceso para la preparacion del compuesto
WO2003004454A1 (en) 2001-07-04 2003-01-16 The Australian National University Linked cyclitols and their polysulfated derivatives
EP1427427B1 (en) 2001-09-12 2011-06-08 SIGMA-TAU Research Switzerland S.A. Derivatives of partially desulphated glycosaminoglycans as heparanase inhibitors, endowed with antiangiogenic activity and devoid of anticoagulating effect
FR2830767B1 (fr) 2001-10-12 2004-03-12 Optis France Sa Dispositif de delivrance de medicaments par iontophorese ou electroporation introculaire
FR2830766B1 (fr) 2001-10-12 2004-03-12 Optis France Sa Dispositif de delivrance de medicaments par iontophorese transpalpebrale
AU2003218215A1 (en) 2002-03-15 2003-09-29 Vertex Pharmaceuticals, Inc. Azolylaminoazines as inhibitors of protein kinases
US7084157B2 (en) 2002-05-17 2006-08-01 Rajeev Raut Ophthalmic pharmaceutical compositions and methods for treating ocular inflammation
AU2003255482A1 (en) 2002-10-02 2004-04-23 Merck Patent Gmbh Use of 4 amino-quinazolines as anti cancer agents
US7785578B2 (en) 2002-10-11 2010-08-31 Aciont, Inc. Non-invasive ocular drug delivery
WO2004043989A2 (en) 2002-11-07 2004-05-27 Medarex, Inc. Human monoclonal antibodies to heparanase
WO2004046122A2 (en) 2002-11-16 2004-06-03 Oxford Glycosciences (Uk) Ltd Benzoxazole, benzthiazole and benzimidazole acid derivatives and their use as heparanase inhibitors
CA2515000A1 (en) 2003-01-31 2004-08-19 Jessie L.-S. Au Methods and compositions for using suramin, pentosan polysulfate, telomerase antisense, and telomerase inhibitors
US20050074497A1 (en) 2003-04-09 2005-04-07 Schultz Clyde L. Hydrogels used to deliver medicaments to the eye for the treatment of posterior segment diseases
US20060269552A1 (en) 2003-06-09 2006-11-30 Oron Yacoby-Zeevi Heparanase activity neutralizing anti-heparanase monclonal antibody and other anti-heparanase antibodies
TWI426080B (zh) 2004-03-04 2014-02-11 Progen Pharmaceuticals Ltd 硫酸化寡醣衍生物
WO2006002088A2 (en) * 2004-06-21 2006-01-05 The Ohio State University Research Foundation Amino-quinazoline derivatives as antitumor agents
FR2873377B1 (fr) 2004-07-23 2006-10-13 Sanofi Synthelabo Derives d'azasucre, inhibiteurs d'heparanases, leur procede de preparation, les compositions en contenant et leur utilisation
US8246949B2 (en) 2004-10-27 2012-08-21 Aciont, Inc. Methods and devices for sustained in-vivo release of an active agent
EP1940507A4 (en) 2005-10-24 2011-04-20 Aciont Inc INTRAOCULAR IONTOPHORETIC DEVICE AND RELEVANT PROCEDURES
FR2893852B1 (fr) 2005-11-29 2010-09-03 Eyegate Pharma Sa Dispositif d'iontophorese oculaire
US20080177220A1 (en) 2006-01-06 2008-07-24 The Curators Of The University Of Missouri Ultrasound-Mediated Transcleral Drug Delivery
US20080027371A1 (en) 2006-07-26 2008-01-31 Higuchi John W Method and device for minimally invasive site specific ocular drug delivery
EP2086553A4 (en) 2006-10-20 2010-12-29 Univ Australian INHIBITION OF EXTRACELLULAR MATRIX DEGRADATION
WO2008134430A1 (en) 2007-04-24 2008-11-06 Novelmed Therapeutics Inc. Methods and compositions of inhibiting complement and cellular activation with dextran sulfate
BRPI0816613A2 (pt) 2007-10-16 2018-10-23 Progen Pharmaceuticals Ltd novos derivados de oligossacarideos sulfatados
US20090170865A1 (en) * 2007-11-30 2009-07-02 University Of Kentucky Research Foundation Treatment of Prostate Cancer with Angiogenesis-Targeting Quinazoline-Based Anti-Cancer Compounds
EP2149580A1 (en) 2008-07-15 2010-02-03 Istituto Scientifico di Chimica E Biochimica "G Ronzoni Mimetics of sulfated oligosaccharides
WO2010009087A1 (en) 2008-07-15 2010-01-21 Eyegate Pharmaceuticals, Inc. Iontophoretic delivery of a controlled-release formulation in the eye
CA2737217A1 (en) * 2008-09-30 2010-04-08 Astrazeneca Ab Heterocyclic jak kinase inhibitors
EP2370155B1 (en) 2008-12-31 2018-07-04 Eyegate Pharmaceuticals, Inc. System for ocular iontophoresis with buffering
AU2010222848A1 (en) 2009-03-09 2011-10-20 Surface Logix, Inc. Rho kinase inhibitors
US8609075B2 (en) 2009-09-30 2013-12-17 Shiseido Company, Ltd. Heparanase activity inhibitor
JP2011074027A (ja) 2009-09-30 2011-04-14 Shiseido Co Ltd ヘパラナーゼ活性阻害剤並びにそれを含有するしわ改善剤及び医薬組成物
JP2011074024A (ja) 2009-09-30 2011-04-14 Shiseido Co Ltd ヘパラナーゼ活性阻害剤並びにそれを含有するしわ改善剤及び医薬組成物
AR079814A1 (es) 2009-12-31 2012-02-22 Otsuka Pharma Co Ltd Compuestos heterociclicos, composiciones farmaceuticas que los contienen y sus usos
US20110189174A1 (en) 2010-02-01 2011-08-04 Afshin Shafiee Compositions and methods for treating, reducing, ameliorating, alleviating, or inhibiting progression of, pathogenic ocular neovascularization
WO2011109877A1 (en) 2010-03-12 2011-09-15 The Australian National University Heparan sulfate replacement therapy
WO2012101544A1 (en) 2011-01-29 2012-08-02 Alembic Pharmaceuticals Limited An improved process for the preparation of pentosan polysulfate or salts thereof
US20140046052A1 (en) 2011-09-21 2014-02-13 Bruce A. Daniels Therapeutic Sulfated Polysaccharides, Compositions Thereof, and Methods for Treating Patients
FR2991876B1 (fr) 2012-06-13 2014-11-21 Vivacy Lab Composition, en milieu aqueux, comprenant au moins un acide hyaluronique et au moins un sel hydrosoluble de sucrose octasulfate
JP6391120B2 (ja) 2012-12-20 2018-09-19 サンフォード−バーンハム メディカル リサーチ インスティテュート ニューロテンシン受容体１の小分子アゴニスト
ITMI20130112A1 (it) 2013-01-24 2014-07-25 Chemi Spa Metodo di qualificazione di preparazioni di pentosan polifosfato, sue materie prime e processi di produzione
JP2017513954A (ja) 2014-04-22 2017-06-01 ニンバス アイリス， インコーポレイテッド Ｉｒａｋ阻害剤およびその使用
WO2016118933A1 (en) 2015-01-22 2016-07-28 Eyegate Pharmaceuticals, Inc. Iontophoretic contact lens

Also Published As

Publication number Publication date
IL267238A (en) 2019-08-29
AU2017376817B2 (en) 2022-03-31
JP2020503377A (ja) 2020-01-30
CA3046997A1 (en) 2018-06-21
EP3555051A1 (en) 2019-10-23
RU2019121873A3 (es) 2021-02-25
WO2018107200A1 (en) 2018-06-21
CN110291073A (zh) 2019-09-27
EP3555051A4 (en) 2020-06-10
RU2019121873A (ru) 2021-01-15
US11718609B2 (en) 2023-08-08
US20210130338A1 (en) 2021-05-06
BR112019012045A2 (pt) 2020-08-18
KR20190093214A (ko) 2019-08-08
AU2017376817A1 (en) 2019-07-11

Similar Documents

Publication Publication Date Title
PH12017501921A1 (en) Novel compounds
PH12017500941A1 (en) Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
EA033163B1 (ru) Ингибиторы глутаминазы
PH12016501750A1 (en) Human plasma kallikrein inhibitors
MY192717A (en) Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
PH12016501600A1 (en) 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease
PH12015502028A1 (en) Ido inhibitors
TW201613901A (en) New compounds
MX366875B (es) Inhibidores de indoleamina 2,3-dioxigenasa (ido).
NZ720478A (en) Autotaxin inhibitor compounds
PH12017500401A1 (en) Therapeutic compounds as inhibitors of the orexin-1 receptor
MX2017004618A (es) Inhibidores de la biosintesis de sulfato de heparano para el tratamiento de enfermedades.
MX2019006863A (es) Inhibidores de heparanasa y uso de los mismos.
MX2019013808A (es) Compuestos desestabilizadores de microtubulina para usarse en el tratamiento del cancer.
MX2022007436A (es) Inhibidores de la autotaxina y sus usos.
MX2019012428A (es) Compuestos de fenil-2-hidroxi-acetilamino-2-metil-fenilo.
MX2017004808A (es) Combinaciones que comprenden siponimod y laquinimod para el tratamiento de la esclerosis multiple.
PH12016500140A1 (en) Heterobicycloaryl rorc2 inhibitors and methods of use thereof
MX2018003563A (es) Nuevos compuestos.
MX2021010297A (es) Inhibidores de calicreina plasmatica humana.
MY180844A (en) Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
PH12017501668A1 (en) Bace1 inhibitors
MX2017003100A (es) Composiciones terapeuticas y nutricionales para trastornos gastrointestinales funcionales.
PH12016502480A1 (en) Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases
MX2016016061A (es) 2,2,2-trifluoroetil-tiadiazinas.